MedTrace Logo

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

NCT03842800 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2020-07-01

No results posted yet for this study

Summary

This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patients with schizophrenia.

Conditions

Interventions

OTHER

MRI

Patients and volunteers will receive an MRI.

DRUG

Ketamine

Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Alan Anticevic, PhD · Yale University School of Medicine, Department of Psychiatry

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-01
Primary Completion
2018-08-31
Completion
2018-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03842800 on ClinicalTrials.gov